Raymond James Starts Coverage of Aardvark Therapeutics With Strong Buy Rating

Raymond James initiates Aardvark Therapeutics with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment.